ReviewJournal of primary care & community health
Recognizing and Treating Major Depression in Fibromyalgia: A Narrative Primer for the Non-Psychiatrist.
Review in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Arthritis and longitudinal trajectories of depressive symptoms and cognition in middle-aged and older adults: a prospective tri-cohort study.Archives of public health = Archives belges de sante publique · 2026Article
- The Relationship Between Pain and Depression in Fibromyalgia: Structural Equation Modeling and Network Analysis.International journal of environmental research and public health · 2026Article
- Persistent Physical Symptoms and Psychosomatic Profiling in Fibromyalgia: A Cross-Sectional Study in a Pain Management Unit.Journal of clinical medicine · 2026Article
- Effects of Aquatic Physiotherapy on Pain and Sleep Quality in Women With Fibromyalgia: A Pre-Post Study.Physiotherapy research international : the journal for researchers and clinicians in physical therapy · 2026Article
- Stakeholder perspectives on depression management: A design thinking exploration for person-centered digital health.PloS one · 2026Article
- Personality Assessment Inventory in Fibromyalgia: Links to Functional, Physical-Somatic, and Emotional Impact.European journal of investigation in health, psychology and education · 2025Article
- The impact of changes in fibromyalgia diagnosis criteria: using NAMCS data (2010-2019) to identify trends.BMC rheumatology · 2025Article
- Fibromyalgia, Depression, and Autoimmune Disorders: An Interconnected Web of Inflammation.Biomedicines · 2025Review
- Psycho-Socio-Behavioural Substrates of Non-Cancer Chronic Pain: A Twin Study in Italian Adults.Journal of pain research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromyalgia (FM) affects 2% to 8% of the general population. FM patients often experience self-stigma and feel rejected by healthcare providers and families, resulting in isolation and distressing symptoms of pain, fatigue, and poor cognitive functioning, increasing the risk of depressive symptoms. Major Depressive Disorder (MDD) is the most common comorbidity in FM patients (Any depression: 43%; MDD: 32%). Genome-wide association studies (GWAS) have identified a common genetic risk loci for major depression and fibromyalgia. Given that even minor symptoms of depression worsen the outcomes of FM patients, clinicians are challenged to identify and manage depression in these patients. However, due to overlapping symptoms, limited screening, and contamination bias, MDD often goes undiagnosed and presents a critical challenge. Unrecognized and untreated MDD in FM patients can exacerbate fatigue, sleep disturbances, and pain, reduce physical functioning, and increase the risk of developing comorbid conditions, such as substance abuse and cardiovascular disease. These comorbidities are associated with a lower treatment response rate, a higher dropout rate, and a greater risk of relapse. Clinicians may effectively identify and treat MDD in FM patients with appropriate pharmacologic agents combined with aerobic exercise and cognitive-behavioral therapies for core FM symptoms, thus significantly reducing symptom severity for both MDD and FM. Such a comprehensive approach will result in a much-improved quality of life. MedLine content was searched via PubMed to identify eligible articles between 1995 and 2023 using search terms fibromyalgia, major depressive disorder, and treatment of depression in fibromyalgia, and the most current information is presented. In this primer for clinicians caring for FM patients, we describe clinically relevant pharmacologic and non-pharmacologic management approaches for treating MDD in FM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.